

December 6, 2013

Announcements

Jennifer Moliterno Gunel Appointed in Neurosurgery

I am pleased to announce that Jennifer Moliterno Gunel, MD has joined the department of Neurosurgery and the Brain Tumor Program at Smilow Cancer Hospital. Dr. Moliterno joins us from the department of Neurosurgery at Memorial Sloan-Kettering Cancer Center where she completed a neurosurgery oncology fellowship. She received her undergraduate and medical degree from The University of Florida. She completed her internship and residency at Yale-New Haven Hospital and served as Chief Resident from 2011-2012. Dr. Moliterno's primary focus is on the surgical management of all types of brain tumors.



Smilow Cancer Hospital Network Research Summit

In an effort to continue to expand our clinical research efforts at the Smilow Cancer Care Centers, we held our third Smilow Cancer Hospital Network Research Summit yesterday at West Campus. I was very happy to see over 60 people, including great representation from the Care Centers, Greenwich and Bridgeport physicians and research staff, as well as our clinical program leaders, CTO staff, and special guests Skip Burris and Deanna Smith from Sarah Cannon Research Institute (SCRI).

The focus of the summit this year was on the relationship between Yale and SCRI, and opportunities for collaboration and excellence in clinical research in the community. Clinical program leaders, as well as new faculty members Steve Gore, Brian Shuch, and Joseph Kim were present to discuss their

from the desk of
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief Smilow Cancer
Hospital at Yale-New Haven



Join Yale Cancer Center
on Facebook

Like us on Facebook 

Follow Yale Cancer
Center on Twitter

Follow us on  twitter

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

Links of Interest

CV Library

The CV library is a new resource

clinical trial portfolios and brainstorm about clinical trial ideas over dinner. Care Center Research leads Kert Sabbath, Jeremy Kortmansky, Debbie Brandt, Wajih Zaheer, and Kevin Jain also met separately with YCC/SCRI leadership to discuss how to improve clinical research efforts.

American Society of Hematology Annual Meeting

Yale Cancer Center and Smilow Cancer Hospital will have a strong presence at the annual meeting beginning tomorrow in New Orleans, with several oral presentations by our clinicians and scientific leaders from the program. If you are attending, please support your colleagues at their presentations. Several posters will be presented as well.

[Protecting the Genome: Mechanisms Targeting Somatic Hypermutation](#)

Result Type: Paper

Number: SCI-13

Presenter: David Schatz

Program: Scientific Program

Session: Genomic Instability and Plasma Cells

Time and Location:

Saturday, December 7, 2013: 2:00 PM-3:30 PM

293-296 (Ernest N. Morial Convention Center)

Sunday, December 8, 2013: 7:30 AM-9:00 AM

293-296 (Ernest N. Morial Convention Center)

[Srf Is Required For Neutrophil Migration In Response To Inflammation](#)

Result Type: Paper

Number: 319

Presenter: Ashley Taylor

Program: Oral and Poster Abstracts

Session: 201. Granulocytes, Monocytes, Macrophages:

Neutrophil Responses to Inflammation and Vascular Injury

Time and Location:

Monday, December 9, 2013: 10:30 AM-12:00 PM

295-296 (Ernest N. Morial Convention Center)

[The Bcl6 RD2 Domain Is Essential For Pre-Germinal Center B Cell Development](#)

Result Type: Paper

Number: 783

Presenter: Chuanxin Huang

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: B Cells and Innate Immune Cells

Time and Location:

Tuesday, December 10, 2013: 7:30 AM-9:00 AM

395-396 (Ernest N. Morial Convention Center)

[Blast Crisis CML Cells Require IFN- \$\gamma\$ Conditioning For Effective GVL Whereas Chronic Phase CML Cells Do Not: An](#)

available to our members, with CVs of post-docs and others looking for positions at Yale. Please browse the listings if you have openings, and send the CVs you receive to share.

[Learn More >>](#)

In the News

Read recent articles featuring experts from Yale Cancer Center.

[Read More >>](#)

Subscribe to Yale Cancer Center Answers on iTunes

Yale Cancer Center's weekly radio program on CT Public Radio is ranked number 2 in the world for cancer programs on iTunes. Subscribe to the show.

[Learn More >>](#)

Yale Cancer Center Grand Rounds

Video presentations from Yale Cancer Center members are now available online.

[Learn More >>](#)

DirectConnect Archives

[Learn More >>](#)

ASCO Connection Blog

Where do we go from here? Thoughts on Improving the Healthcare System

[Read More >>](#)

Events

December 6; 7:00 AM Yale CME/New England Otolaryngological Society

TAC N-107

New Technologies in

Otolaryngology

Ken Yanagisawa MD, FACS

[Learn More >> \(PDF\)](#)

December 6; 2:00 PM YCC Special Seminar

WWW 208

Antitumor T-Cell Immunity Delays the Emergence of Melanoma

Resistance to Vemurafenib:

Defining the Principles of

Combination Therapy from Mice to

[Explanation For Chronic Phase CML GVL-Sensitivity](#)

Result Type: Paper

Number: 2013

Presenter: Warren Shlomchik

Program: Oral and Poster Abstracts

Session: 702. Experimental Transplantation: Immune Function, **GVHD and Graft-versus-Tumor Effects:** Poster I
Time and Location:

Saturday, December 7, 2013: 5:30 PM-7:30 PM

Hall G (Ernest N. Morial Convention Center)

[Both Intermittent and Continuous Dosing Regimens Of Pomalidomide Mediate Broad Activation Of Innate and Adaptive Immunity In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial](#)

Result Type: Paper

Number: 1949

Presenter: Kavita Dhodapkar

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Time and Location:

Saturday, December 7, 2013: 5:30 PM-7:30 PM

Hall G (Ernest N. Morial Convention Center)

[Graft-Versus-Host-Disease Recruits Both Monocyte and Pre-Conventional Dendritic Cell-Derived Tissue Antigen Presenting Cells Independent Of CCR2 and CCR6](#)

Result Type: Paper

Number: 4463

Presenter: Sarah Morin-Zorman

Program: Oral and Poster Abstracts

Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster III

Time and Location:

Monday, December 9, 2013: 6:00 PM-8:00 PM

Hall G (Ernest N. Morial Convention Center)

[Host Tissue PD-1 Pathway Contribute To Murine Chronic Graft-Versus-Host Disease Via Th1+Th17+ Cells](#)

Result Type: Paper

Number: 3244

Presenter: Hideaki Fujiwara

Program: Oral and Poster Abstracts

Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster II

Time and Location:

Sunday, December 8, 2013: 6:30 PM-8:30 PM

Hall G (Ernest N. Morial Convention Center)

[Comparison Of Intermittent and Continuous Dosing Regimens Of Pomalidomide In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial](#)

Result Type: Paper

Number: 3205

Humans

Nicolas Acquavella, MD

[Learn More >> \(PDF\)](#)

December 8; 6:00 PM

Yale Cancer Center Answers

WNPR

Translational Medicine

Theresa LaValle, PhD

[Learn More >>](#)

December 10; 9:30 AM

Pathology Special Seminar

Pathology Conference Room, BML 137

Novel Activities, Metabolism, and Expression of Estrogen Receptor Activators in Osteoblasts

Michael Centrella PhD and Thomas L. McCarthy, PhD

[Learn More >> \(PDF\)](#)

December 10; 12:00 PM

Yale Cancer Center Grand Rounds

Park Street Auditorium

Cancer and the Media:

A Troubled Marriage

Robert Bazell

[Learn More >>](#)

December 11; 1:00 PM

Cancer Metabolism Interest Group & Signal Transduction Meeting

Giarman Room, SHM B-201

Epigenetic Regulation of Cancer Signaling and Metabolism

Marcus Bosenberg, MD, PhD

[Learn More >> \(PDF\)](#)

December 11; 1:00 PM

Office of Cooperative Research Sponsors

Yale Office of Cooperative Research

SBIR Office Hours with Connecticut Innovations

Merrie London

[Learn More >>](#)

December 12; 12:00 PM

Schwartz Rounds

55 Park Street

When Things Go Better Than Expected

[Learn More >>](#)

Presenter: Kartik Sehgal
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation:
Poster II

Time and Location:
Sunday, December 8, 2013: 6:30 PM-8:30 PM
Hall G (Ernest N. Morial Convention Center)

[Two Photon Intravital Microscopy Reveals CD4+ T Cells Making Cognate Interactions With Tissue Dendritic Cells In Skin Graft-Versus-Host-Disease](#)

Result Type: Paper
Number: 2004

Presenter: Sarah Morin-Zorman
Program: Oral and Poster Abstracts
Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I
Time and Location:
Saturday, December 7, 2013: 5:30 PM-7:30 PM
Hall G (Ernest N. Morial Convention Center)

[Expression Of Mutant Spliceosomal Protein SF3B1 Results In Dysregulated Hematopoietic Maturation](#)

Result Type: Paper

Number: 2773

Presenter: Manoj Pillai
Program: Oral and Poster Abstracts
Session: 633. Myelodysplastic Syndromes: Poster II
Time and Location:
Sunday, December 8, 2013: 6:30 PM-8:30 PM
Hall E (Ernest N. Morial Convention Center)

[Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution](#)

Result Type: Paper

Number: 596

Presenter: Dan-Avi Landau
Program: Oral and Poster Abstracts
Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Epigenetics of Hematopoiesis and Leukemia
Time and Location:
Monday, December 9, 2013: 4:30 PM-6:00 PM
395-396 (Ernest N. Morial Convention Center)

[Enrichment Of Embryonal Stem Cell Signature and Persistent Genomic Complexity In Residual Disease Following Pomalidomide Therapy In Myeloma](#)

Result Type: Paper

Number: 4200

Presenter: Rakesh Verma
Program: Oral and Poster Abstracts
Session: 661. Malignant Stem and Progenitor Cells: Poster III
Time and Location:

December 12; 5:00 PM
Yale Humanities in Medicine/Howard Spiro Lecture Series

TAC N-107
Edward Muybridge, Anatomist and Murderer: The Human Body, Motion Studies, and the Birth of Moving Pictures
Edward Ball
[Learn More >>](#)

December 13; 12:00 PM
YCC Research in Progress

WW 208
New Approaches to the Treatment of Advanced Metastatic Bladder Cancer
Daniel Petrylak, MD
[Learn More >> \(PDF\)](#)

December 13; 1:00 PM
YCC Molecular Virology Research Program

SHM I-116
Host Cell Factors in HSV-1 Nuclear Egress
Christian Schlieker, PhD
[Learn More >> \(PDF\)](#)

December 15; 6:00 PM
Yale Cancer Center Answers

WNPR
Clinical Trials for Hematologic Malignancies
Steven Gore, MD
[Learn More >>](#)

December 16; 1:00 PM
Office of Cooperative Research Sponsors

Yale Office of Cooperative Research
Venture Capital Office Hours with Connecticut Innovations
Margaret Cartiera, PhD
[Learn More >>](#)

December 17; 9:30 AM
Pathology Research in Progress Talks

BML 137
Molecular Diagnosis of Melanocytic Lesions by Mass Spectrometry
Rossitza Lazova, MD
TBA
Lauren Moore
[Learn More >>](#)

Monday, December 9, 2013: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)

[PD-L1 and PD-L2 Protect The Heart In a T-Cell Receptor Transgenic Model Of Graft-Versus Host Disease](#)

Result Type: Paper
Number: 4479
Presenter: Warren Shlomchik
Program: Oral and Poster Abstracts
Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster III
Time and Location:
Monday, December 9, 2013: 6:00 PM-8:00 PM
Hall G (Ernest N. Morial Convention Center)

[A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients](#)

Result Type: Paper
Number: 4356
Presenter: Juliet Fraser
Program: Oral and Poster Abstracts
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III
Time and Location:
Monday, December 9, 2013: 6:00 PM-8:00 PM
Hall G (Ernest N. Morial Convention Center)

[RP6530, a Dual PI3K \$\delta\$ / \$\gamma\$ Inhibitor, Attenuates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma \(CTCL\) Cells](#)

Result Type: Paper
Number: 4418
Presenter: Julia Lewis
Program: Oral and Poster Abstracts
Session: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster III
Time and Location:
Monday, December 9, 2013: 6:00 PM-8:00 PM
Hall G (Ernest N. Morial Convention Center)

[Glucose Phosphate Isomerase Deficiency In 2 Patients With Novel Mutations Presenting As Severe Neurologic Abnormalities and Transfusion Dependent Hemolytic Anemia](#)

Result Type: Paper
Number: 947
Presenter: Mammen Puliylal
Program: Oral and Poster Abstracts
Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster I
Time and Location:
Saturday, December 7, 2013: 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)

[Activation Induced Cytidine Deaminase-Associated DNA Repair Pathways Influence Germinal Center B Cell](#)

**December 17; 12:00 PM
Yale Cancer Center Grand Rounds**

Park Street Auditorium
TBA
Scott Kopetz, MD, PhD, FACP
[Learn More >>](#)

**December 18; 5:30 PM
Yale Cancer Center and Smilow Cancer Hospital Annual Holiday Party**

Peabody Museum
[Learn More >> \(PDF\)](#)

**December 19; 9:00 AM
Therapeutic Radiology Grand Rounds**

Smilow, LL-412, Room E
Patient Safety Presentation
Peter Herbert, MD and Thomas Balcezak, MD
[Learn More >>](#)

**December 20; 12:00 PM
YCC Research in Progress Meeting**

NP4-101A
Next Generation Sequencing of Triple Negative Breast Cancer
Lajos Pusztai, MD
[Learn More >>](#)

Employment Opportunities

We seek your assistance in the recruitment of qualified Oncology Research Nurses to join the Cancer Center for full time research opportunities. Positions traditionally require a minimum of BSN and 4 years of research nursing experience with a strong preference within oncology. In lieu of research experience, trained oncology nurses with little or no research experience are considered for positions of the same level. Should you know of any potential candidates, please encourage them to go on-line to www.yale.edu/jobs and navigate to the STARS employment website in search of positions 18343BR and 18943BR,

[Lymphomagenesis](#)

Result Type: Paper

Number: 1247

Presenter: Xiwen Gu

Program: Oral and Poster Abstracts

Session: 601. Chromosomal Rearrangements and DNA

Repair: Poster I

Time and Location:

Saturday, December 7, 2013: 5:30 PM-7:30 PM

Hall E (Ernest N. Morial Convention Center)

[Enhancers and Super Enhancers Are Associated With Genes That Control Phenotypic Traits In Primary Human Erythroid Cells](#)

Result Type: Paper

Number: 1200

Presenter: Vincent Schulz

Program: Oral and Poster Abstracts

Session: 503. Hematopoiesis: Regulation of Gene

Transcription: Poster I

Time and Location:

Saturday, December 7, 2013: 5:30 PM-7:30 PM

Hall E (Ernest N. Morial Convention Center)

[The Patient With Transfusion-Dependent Anemia: Diagnosis and Directed Management With Targeted Next Generation Sequencing and Copy Number Analysis](#)

Result Type: Paper

Number: 3419

Presenter: Vincent Schulz

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster III

Time and Location:

Monday, December 9, 2013: 6:00 PM-8:00 PM

Hall E (Ernest N. Morial Convention Center)

[Histones To The Cytosol: Role Of Nuclear Protein Export In Erythroid Nuclear Condensation](#)

Result Type: Paper

Number: 310

Presenter: Amalia Figueroa

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron II

Time and Location:

Monday, December 9, 2013: 10:30 AM-12:00 PM

353-355 (Ernest N. Morial Convention Center)

[Blast Crisis CML Cells Require IFN- \$\gamma\$ Conditioning For Effective GVL Whereas Chronic Phase CML Cells Do Not: An Explanation For Chronic Phase CML GVL-Sensitivity](#)

Result Type: Paper

Number: 2013

Presenter: Warren Shlomchik

upload the resume and apply. They may also contact [Sandra Greer](#) for further information.

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

 Forward to a Friend

Program: Oral and Poster Abstracts
 Session: 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I
 Time and Location:
Saturday, December 7, 2013: 5:30 PM-7:30 PM
 Hall G (Ernest N. Morial Convention Center)

[FANCD2 and RAD51 Regulate PCNA Monoubiquitination and Translesion Synthesis](#)

Result Type: Paper
Number: 3712
Presenter: Gary Kupfer
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster III
Time and Location:
Monday, December 9, 2013: 6:00 PM-8:00 PM
 Hall E (Ernest N. Morial Convention Center)

Yale Participation at San Antonio Breast Cancer Symposium

Next week will also mark an exciting week for members of our Breast Center as they present research findings at the annual San Antonio Breast Cancer Symposium. Our presence at this meeting is growing each year, and I'm pleased that we will have such a broad array of presentations from our faculty this year.

Wednesday, December 11 Poster Discussion Session

5:00 pm - 7:00 pm	POSTER DISCUSSION 2: Body Mass, Exercise, and Breast Cancer - Ballroom B
	Pamela J. Goodwin, MD, MSC, FRCP and Melinda Liggett Irwin, PhD, MPH

Wednesday, December 11 Poster Session (5-7 pm)

P1-08-16	Deep sequencing of breast tumor biopsies reveals an association between pathologic complete response and reduction of TP53 clonal abundance upon brief exposure to therapy Williams N, Varadan V, Miskimen K, Vadodkar A, Poruban D, Edelheit S, Gilmore H, Maximuk S, Sinclair N, Lezon-Geyda K, Abu-Khalaf M, Sikov W, Harris L.
P1-08-42	High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Serra V, Parra JL, Prudkin L, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Piccart M, Baselga J.
P1-08-09	EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial Rimm DL, Holmes F, Schalner K, Bradbury I, Zarrella F.

Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Puztai L, Perez E.

Thursday, December 12 Poster Session (7:30 - 9:00 am)

P2-11-04	Expression of immune checkpoint related genes are prognostic in untreated breast cancer Bianchini G, Rossi CM, Iwamoto T, Karn T, Callari M, Kelly CM, Puztai L, Gianni L.
P2-11-22	The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receipt Rutter C, Mancini B, Gross C, Aminawung J, Chagpar A, Saglam O, Hofstatter E, Abu-Khalaf M, Evans S.
P2-10-02	PD-L1 protein expression is a prognostic biomarker in breast cancer Wimberly H, Schalper K, Chen L, Velcheti V, Puztai L, Rimm D.

Thursday, December 12 General Session

10:00 am	S3-03. Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study Irwin ML, Cartmel B, Gross C, Ercolano E, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J.
10:45 am	S3-06. Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer Jeselsohn RM, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Cristofanilli M, Arteaga CL, Balko J, Gilmore L, Schnitt S, Come SE, Puztai L, Stephens P, Miller VA, Brown M.

Thursday, December 12 Poster Discussion Session (5-7 pm)

PD4-6	Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers Shi W, Balazs B, Qi Y, Györfy B, Wang B, Liu C-G, Shiang CY, Valero V, Moulder-Thompson S, Avritscher R, Powis G, Hortobagyi GN, Natowicz R, Wali V, Weinstein J, Symmans WF, Puztai L.
--------------	--

Thursday, December 12 Poster Discussion Session (5-7 pm)

P3-05-05	Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer Györfy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Puztai L.
-----------------	---

P3-14-02	Patterns of the use of primary systemic therapy in the United States Mougalian SS, Abu-Khalaf MM, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Puztai L, Chagpar AB.
-----------------	--

Friday, December 13 Poster Session (7:30 - 9:00 am)

P4-04-02	RNA-seq reveals functional lncRNAs associated with estrogen-receptor status in breast cancer Banerjee N, Chothani S, Kamalakaran S, Varadan V, Miskimen K, Vadodkar A, Abu-khalaf M, Sikov W, Harris LN, Dimitrova N.
P4-04-06	Systematic analysis of molecular subgroups and age in patients with breast cancer Liedtke C, Karn T, Gluz O, Becker S, Puztai L, Holtrich U, Rody A.
P4-04-07	Heterogeneous gene fusions detected by RNASeq show enrichment of insulin signaling pathway genes in breast cancer Varadan V, Agrawal V, Kamalakaran S, Banerjee N, Miskimen K, Vadodkar A, Abu-Khalaf M, Sikov W, Harris LN, Dimitrova N.
P4-05-09	Estrogen receptor (ER) mRNA expression and molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by immunohistochemistry Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Doihara H, Symmans W, Puztai L.
P4-06-05	Transcriptional heterogeneity correlates with chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype Jiang T, Shi W, Ononye S, Han G, Wali V, Puztai L, Hatzis C.

Friday, December 13 General Session

10:00 am	S5-03. Discussant (S5-01 to S5-02) Lajos Puztai, MD, DPHIL
----------	--

Friday, December 13 General Session

3:30 pm	S6-02. Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy Symmans WF, Wei C, Gould R, Zhang Y, Hunt KK, Buchholz TA, Valero V, Hortobagyi GN, Puztai L, Hatzis C.
---------	---

Friday, December 13 Poster Discussion Session (5-7 pm)

PD5-6	Sustained hyperactivated mTOR & JAK2/STAT3 pathways in inflammatory breast cancer (IBC): Evidence for mTOR plus JAK2 therapeutic targeting Jhaveri K, Teplinsky E, Arzu R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine PH, Hashmi S, Hoffman HJ, Paul L, Singh B, Goldberg JD, Hochman T, Formenti S, Valeta A, Moran MS,
--------------	--

Schneider R.J..

Friday, December 13 Poster Session (5-7 pm)

- P5-13-04** What's your excuse?: Reasons women with a first degree family history of breast cancer don't get mammograms
Hibler L, Hofstatter EW, Chagpar AB.
- P5-13-05** Richer and wiser: Factors correlated with chemoprevention use in the United States
Hofstatter EW, Lannin D, Horowitz N, Killelea B, Tsangaris T, Puztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A.

Saturday, December 14 Poster Session (7:30 - 9:00 am)

- P6-05-19** Epithelial expression of PD-L1 mRNA is associated with increased TILs and better outcome in breast carcinomas
Schalper KA, Velcheti V, Wimberly H, Carvajal D, Puztai L, Rimm DL.
- P6-06-09** Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?
Abu-Khalaf MM, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Puztai L, Gross C, Russell K, Russell R.
- P6-06-37** Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes
Hatzis C, Gould RE, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans WF, Puztai L.
- P6-07-05** Regional variation in Medicare expenditures for older women with localized breast cancer
Xu X, Soulos PR, Herrin J, Ross JS, Saraf A, Roberts KB, Killelea BK, Wang S, Long JB, Wang R, Ma X, Gross CP.
- P6-11-03** Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience
Abu-Khalaf MM, Hatzis C, Chung G, DiGiovanna M, Sanft T, Hofstatter E, Puztai L, Yu J, Chiang V.

Holiday Party

I hope you will join us for our annual Yale Cancer Center and Smilow Cancer Hospital holiday party at the Peabody Museum on Wednesday, December 18 from 5:30-7:30 PM. Everyone is invited, along with their families, to join in this festive evening and celebrate the holiday season together. I look forward to seeing you all there!

[Learn More >>](#)

□

Notables

Santo Galatioto has been appointed as the **Human Resources Generalist** for Yale Cancer Center and the Department of Urology. Santo has 26 years of experience at Yale University, including 21 years in labor relations.

In addition, Yale Cancer Center continues to benefit from the continued support of **Lauren Slater** as the Interim HR generalist. Lauren remains the key contact point for all employee relations' matters and other HR activities.

Closer to Free



There have been numerous events dedicated to raising funds for Closer to Free this fall. Recently, the Guilford High School Boys and Girls Soccer teams presented a generous check to support breast cancer awareness, research and treatment, in honor of survivor Amy Stinton, whose wife, Regina Sullivan, works at GHS. These funds were raised by the sale of the specially designed tee-shirts worn by the senior boys pictured.

Every gift, large or small, has a positive impact on the patients and their families, researchers and care providers - all of us who make up the Closer to Free community. Information about making a donation or organizing an event is available on the Give Closer to Free [website](#) or by contacting [Susan Frankenbach](#). Don't forget to "like" us on [Facebook](#)!

Funding and Award Opportunities

Tobacco Center of Regulatory Science 2014 Pilot Program
The Yale Tobacco Center of Regulatory Science (TCORS) is offering funding for pilot projects to initiate research relating to understanding tobacco additives and modified risk tobacco products through behavioral, molecular, laboratory, pharmacological, epidemiological, and economic sciences that

involves humans (both clinical & epidemiological research) and animals (basic research). We are particularly interested in studies of menthol, flavors, and e-cigarettes and studies using novel techniques.

Up to 5 pilot projects will be funded at the level of \$25,000 to \$100,000 (direct costs only), with higher levels of funding available for projects that incorporate more expensive technologies (such as neuroimaging). The project must be completed in 1 budget year.

Application Deadline: December 16, 2013

[Learn More >>](#)

Edward Mallinckrodt, Jr., Foundation Mallinckrodt Scholars

To support early-stage investigators engaged in basic biomedical research that has the potential to significantly advance the understanding, diagnosis, or treatment of disease.

- Candidates should hold an MD and/or PhD degree and must be an Assistant or Associate Professor in the fifth to eighth year of a tenure-track position.
- Candidate may have already received independent research funding (R01 or other major awards) for other projects.
- This award is designed to move the proposed Mallinckrodt project forward to the point where R01 or other independent funding can be obtained.
- \$100,000 per year for 4 years. (\$400,000)

Application Deadline: December 11, 2013

[Learn More >>](#)

Avon Foundation Research Grant Program

Supports research projects aimed at understanding the causes of breast cancer, prevention or developing new tests to assess risk. Funds can also be requested to develop new treatments for unmet needs in breast cancer. Up to \$150,000 per year for 2 years. (\$300,000 maximum) An optional 3rd year can be sought during Year 2.

Letter of Intent Deadline: January 31, 2014

[Learn More >>](#)

Employee Profile: Laura Radulski, RN

The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being

*done here, and the dedication and values we possess.
To suggest someone to be profiled, please contact
Emily Fenton.*

Laura Radulski, RN for the outpatient infusion clinic on the first floor of Smilow, was inspired to start a career as a nurse after her husband was diagnosed with cancer, and she saw the impact nurses can have on a patient's care, and the family unit as a whole. Her husband is now doing well, but her passion for helping others remained strong. Laura spent six years as an inpatient nurse on Smilow 14, but recently moved to the outpatient setting in order to be a part of the other side of a patient's journey.

In the outpatient setting Laura administers chemotherapy, blood products, and anything else a patient may require, such as electrolytes for dehydration. She works closely with the Practice Nurses, PA's, and the other infusion nurses administering care to patients with breast and gynecologic cancers. Educating patients about what to expect, and possible side effects, is another part of the outpatient setting.

Laura commented, "Seeing the grace and dignity with which these women carry themselves when they come in for treatment is inspiring. Sometimes they have small children with them and it is hard not to let it affect you, but my job is to be there for my patients and support them during a very scary and vulnerable time."

Reaching out to patients while they are outside of the clinic is another large component of working in the outpatient infusion clinic. Laura explained that keeping in touch with patients once they are home is so important in order to prevent admission into the hospital. Addressing issues at home before they become a problem is the goal, and providing resources, such as coordinating home care, so that they can stay out of the hospital.

While working on Smilow 14, Laura was awarded the Virginia Henderson Award, which honors individuals that have made outstanding contributions to nursing in the areas of practice, education, administration, political action, and service. She commented, "It was such an honor to receive this award, knowing how amazing all the nurses are that I work with. I was touched to know that they feel comfortable coming to me for advice or with questions, as I do with them."

Recent Publications

Taxanes: their impact on gynecologic malignancy.
Schwab CL, English DP, Roque DM, Santin AD.

Anticancer Drugs. 2013 Dec 1.

[Read More >>](#)

New possibilities and potential benefits for local control in locally recurrent pancreatic cancer.

Lloyd S, Chang BW.

J Gastrointest Oncol. 2013 Dec;4(4):340-342.

[Read More >>](#)

Healthy eating for life: rationale and development of an English as a second language (ESL) curriculum for promoting healthy nutrition.

Martinez JL, Rivers SE, Duncan LR, Bertoli M, Domingo S, Latimer-Cheung AE, Salovey P.

Transl Behav Med. 2013 Dec;3(4):426-433.

[Read More >>](#)

Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis.

Hedhli N, Kalinowski A, S Russell K.

Curr Pharm Des. 2013 Nov 25.

[Read More >>](#)

Identification of PLX4032-Resistance Mechanisms and Implications for Novel RAF Inhibitors.

Choi J, Landrette S, Wang T, Evans P, Bacchiocchi A, Bjornson R, Cheng E, Stiegler AL, Gathiaka S, Acevedo O, Boggon TJ, Krauthammer M, Halaban R, Xu T.

Pigment Cell Melanoma Res. 2013 Nov 27.

[Read More >>](#)

Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method.

Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF.

PLoS One. 2013 Nov 21;8(11):e79901.

[Read More >>](#)

Nurse Navigators in Early Cancer Care: A Randomized, Controlled Trial.

Wagner EH, Ludman EJ, Aiello Bowles EJ, Penfold R, Reid RJ, Rutter CM, Chubak J, McCorkle R.

J Clin Oncol. 2013 Nov 25.

[Read More >>](#)

Thyroid Cancer.

Carling T, Udelsman R.

Annu Rev Med. 2013 Nov 20.

[Read More >>](#)

Hypoxia and regulation of cancer cell stemness.

Yun Z, Lin Q.

Adv Exp Med Biol. 2014;772:41-53.

[Read More >>](#)

SomatiCA: Identifying, Characterizing and Quantifying Somatic Copy Number Aberrations from Cancer Genome Sequencing Data.

Chen M, Gunel M, Zhao H.
PLoS One. 2013 Nov 12;8(11):e78143.

[Read More >>](#)

'Race' and Prostate Cancer Mortality in Equal-access Healthcare Systems.

Graham-Steed T, Uchio E, Wells CK, Aslan M, Ko J, Concato J.

Am J Med. 2013 Dec;126(12):1084-8.

[Read More >>](#)

PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer.

Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, Narod SA.

J Natl Cancer Inst. 2013 Nov 21.

[Read More >>](#)

Construction and analysis of multiparameter prognostic models for melanoma outcome.

Rothberg BE, Rimm DL.
Methods Mol Biol. 2014;1102:227-58.

[Read More >>](#)

[Forward Email to a Colleague](#)



Try it FREE today.

This email was sent to renee.gaudette@yale.edu by renee.gaudette@yale.edu | [Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).
Yale Cancer Center | 333 Cedar Street | WWW 208 | New Haven | CT | 06520